Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients

Kathelijn Fischer, Ronan Pendu, Carina J. van Schooten et al. · 2009

Read Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients by Kathelijn Fischer, Ronan Pendu, Carina J. van Schooten et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006745.txt.

Description

Kathelijn Fischer and colleagues built models to predict treatment dosing in severe haemophilia in PLOS ONE in 2009. Factor VIII is the clotting protein these patients lack. How long a dose lasts depends heavily on von Willebrand factor. That partner protein protects factor VIII in the blood. Its level before infusion tracks with factor VIII half-life.

The team used standardized half-life studies to build prediction models. Blood group turned out to change the picture. Separate models were needed for group O and non-O patients. Predicting half-life in advance helps doctors tailor doses to each patient. Better tailoring can prevent bleeds while avoiding wasted concentrate.

Catalog record

CREATORKathelijn Fischer, Ronan Pendu, Carina J. van Schooten et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006745

Browse the full library · About the Tower of Babel